APS Foundation of America, Inc.

01/01/2026

01/01/2026

“She’s a lot.”
Maybe.
But if you carried what I carry, you’d be a lot too.

31/12/2025

Today is the last day to support the APS Foundation of America’s year‑end campaign.

APS (Antiphospholipid Antibody Syndrome) is often misdiagnosed or missed entirely—putting lives at risk. Your gift today helps us:

Educate patients, families, and healthcare providers
Support those living with this chronic, often invisible illness
Advocate for earlier diagnosis and better care
Help us provide microgrants to research teams around the country

Please don’t wait—midnight is the deadline.

Donate now: https://apsfa.org/donate

30/12/2025

Lupus in the News: New research has found more about the beneficial effects of higher doses (>400 mg/day) of hydroxychloroquine (HCQ) on lupus - in particular on some cardiovascular disease. HCQ has some adverse effects and changes in dosages should always be discussed with your healthcare providers. Yet, studies continue to show that many lupus patients are “underdosed” and could benefit from higher dosages.

Link: https://ow.ly/Osv150XP85K

30/12/2025

Read more https://www.researchgate.net/publication/395094619_Hydroxychloroquine_and_pregnancy_outcomes_in_patients_with_anti-phospholipid_syndrome_a_systematic_review_and_meta-analysis about this topic we have supported

✨ 𝗡𝗲𝘄 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗯𝗿𝗶𝗻𝗴𝘀 𝗵𝗼𝗽𝗲𝗳𝘂𝗹 𝗻𝗲𝘄𝘀 𝗳𝗼𝗿 𝗽𝗲𝗼𝗽𝗹𝗲 𝘄𝗶𝘁𝗵 𝗔𝗣𝗦 𝗽𝗹𝗮𝗻𝗻𝗶𝗻𝗴 𝗮 𝗽𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆. 🤰🏽

A 2025 systematic review has found that adding 𝗵𝘆𝗱𝗿𝗼𝘅𝘆𝗰𝗵𝗹𝗼𝗿𝗼𝗾𝘂𝗶𝗻𝗲 (𝗛𝗖𝗤) to the usual aspirin + heparin treatment was linked with:
💙 𝗛𝗶𝗴𝗵𝗲𝗿 𝗹𝗶𝘃𝗲 𝗯𝗶𝗿𝘁𝗵 𝗿𝗮𝘁𝗲𝘀
💙 𝗙𝗲𝘄𝗲𝗿 𝗽𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆 𝗰𝗼𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 (𝘀𝘂𝗰𝗵 𝗮𝘀 𝗽𝗿𝗲-𝗲𝗰𝗹𝗮𝗺𝗽𝘀𝗶𝗮, 𝗴𝗿𝗼𝘄𝘁𝗵 𝗿𝗲𝘀𝘁𝗿𝗶𝗰𝘁𝗶𝗼𝗻 𝗼𝗿 𝗽𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆 𝗹𝗼𝘀𝘀)
💙 𝗚𝗼𝗼𝗱 𝘀𝗮𝗳𝗲𝘁𝘆 𝘄𝗶𝘁𝗵 𝗻𝗼 𝗺𝗮𝗷𝗼𝗿 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗿𝗲𝗽𝗼𝗿𝘁𝗲𝗱

Across 750 pregnancies, those taking HCQ had 𝗯𝗲𝘁𝘁𝗲𝗿 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝗼𝘃𝗲𝗿𝗮𝗹𝗹, including people in higher-risk groups.

🔹 This doesn’t mean HCQ is right for everyone, and APS Support UK can’t advise on individual treatment — but it’s a really encouraging step forward in APS pregnancy research.
🔹 Always speak to your specialist team about what’s safe and appropriate for 𝙮𝙤𝙪.

💬 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝘀𝘁𝘂𝗱𝘆 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 𝗯𝗲𝗹𝗼𝘄. 👇

30/12/2025

Read more: https://pubmed.ncbi.nlm.nih.gov/41287141/ on this topic

A large US study has found that 𝗯𝗼𝘁𝗵 𝗮𝗱𝘂𝗹𝘁𝘀 𝗮𝗻𝗱 𝗰𝗵𝗶𝗹𝗱𝗿𝗲𝗻 𝘄𝗶𝘁𝗵 𝗮𝗻𝘁𝗶𝗽𝗵𝗼𝘀𝗽𝗵𝗼𝗹𝗶𝗽𝗶𝗱 𝘀𝘆𝗻𝗱𝗿𝗼𝗺𝗲 (𝗔𝗣𝗦) 𝗮𝗿𝗲 𝗺𝗼𝗿𝗲 𝗹𝗶𝗸𝗲𝗹𝘆 𝘁𝗼 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲 𝗰𝗲𝗿𝘁𝗮𝗶𝗻 𝗲𝗮𝗿-𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝘀𝘆𝗺𝗽𝘁𝗼𝗺𝘀—such as hearing loss, tinnitus and vertigo—than people without APS.

The reasons aren’t yet clear, and the study highlights the need for more research into how APS may affect the inner ear.

𝗜𝗳 𝘆𝗼𝘂’𝗱 𝗹𝗶𝗸𝗲 𝘁𝗼 𝗿𝗲𝗮𝗱 𝘁𝗵𝗲 𝗮𝗯𝘀𝘁𝗿𝗮𝗰𝘁, 𝘆𝗼𝘂 𝗰𝗮𝗻 𝗳𝗶𝗻𝗱 𝗶𝘁 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 𝗯𝗲𝗹𝗼𝘄. 👇

If you’re experiencing new ear-related symptoms, please speak to your GP or specialist.

30/12/2025

Read more https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1722080/full on this topic

𝗡𝗲𝘄 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵: 𝗛𝗼𝘄 𝘁𝗵𝗲 𝗜𝗺𝗺𝘂𝗻𝗲 𝗦𝘆𝘀𝘁𝗲𝗺 𝗔𝗳𝗳𝗲𝗰𝘁𝘀 𝗣𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆 𝗶𝗻 𝗔𝗣𝗦 🤰🏽

A new review highlights that obstetric APS isn’t only about blood clots — the immune system also plays a major role in pregnancy complications.

Researchers found that antiphospholipid antibodies can:
✨ Disrupt placenta development
✨ Affect how trophoblast cells grow and invade
✨ Overactivate the complement system
✨ Trigger excess NETs (a type of inflammatory response)

Together, these changes can make it harder for the placenta to function properly, increasing the risk of miscarriage, pre-eclampsia, and stillbirth.

The more we understand these pathways, the closer we get to better, more targeted treatments for people with APS in pregnancy.

🔗 We’ll share the study link in the comments for those who’d like to read the full paper.

30/12/2025

Read more: https://pmc.ncbi.nlm.nih.gov/articles/PMC12661305/ about this topic

A recent review looks at 𝗮𝗻𝘁𝗶𝗽𝗵𝗼𝘀𝗽𝗵𝗼𝗹𝗶𝗽𝗶𝗱 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 (𝗮𝗣𝗟𝘀) 𝗶𝗻 𝗹𝗶𝘃𝗲𝗿 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 — 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗵𝗼𝘄 𝘁𝗵𝗲𝘆 𝗺𝗮𝘆 𝗮𝗳𝗳𝗲𝗰𝘁 𝗽𝗲𝗼𝗽𝗹𝗲 𝘂𝗻𝗱𝗲𝗿𝗴𝗼𝗶𝗻𝗴 𝗹𝗶𝘃𝗲𝗿 𝘁𝗿𝗮𝗻𝘀𝗽𝗹𝗮𝗻𝘁𝗮𝘁𝗶𝗼𝗻.

One of the most important findings is that while aPLs are often seen in liver conditions, this 𝗱𝗼𝗲𝘀 𝗻𝗼𝘁 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗶𝗰𝗮𝗹𝗹𝘆 𝗺𝗲𝗮𝗻 𝗔𝗣𝗦, and current evidence does 𝙣𝙤𝙩 show a clear increase in transplant-related clotting risk for people who have aPLs but no APS diagnosis.

For patients with confirmed APS, transplantation can still be successful, but it requires careful specialist management around surgery.

🔗 𝗙𝘂𝗹𝗹 𝘀𝘁𝘂𝗱𝘆 𝗹𝗶𝗻𝗸 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀. 👇

30/12/2025

Read more: https://pubmed.ncbi.nlm.nih.gov/41308951/ on this interesting topic. What are your thoughts?

🧠 New APS stroke study (design paper – no results yet)

A new clinical trial called APS-STROKE is testing whether a clopidogrel-based antiplatelet approach could be an alternative to warfarin (INR 2.0–3.0) to help prevent another stroke/TIA in some people with antiphospholipid syndrome (APS).

✅ Who the trial includes:
• Adults with definite APS (Sydney criteria) and prior ischaemic stroke or TIA

🚫 Who the trial excludes (important):
• Higher-risk APS (e.g., triple positivity or persistently high antibody titres)
• Systemic lupus erythematosus (SLE)
• People who are pregnant/breastfeeding or planning pregnancy during the study

What they’ll track:
• Stroke/TIA, other clots, major bleeding, and deaths over up to 4 years

Key point:
This publication explains the study plan. It does not tell us which treatment is better yet.

𝗪𝗮𝗻𝘁 𝘁𝗼 𝗿𝗲𝗮𝗱 𝗶𝘁? 𝗙𝗶𝗻𝗱 𝘁𝗵𝗲 𝗹𝗶𝗻𝗸 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 𝗯𝗲𝗹𝗼𝘄.👇

30/12/2025

Read more: https://pmc.ncbi.nlm.nih.gov/articles/PMC12664236/ on this topic

🫁 𝗖𝗮𝗻 𝗮𝗻𝘁𝗶𝗽𝗵𝗼𝘀𝗽𝗵𝗼𝗹𝗶𝗽𝗶𝗱 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝗯𝗲 𝗹𝗶𝗻𝗸𝗲𝗱 𝘁𝗼 𝘁𝗶𝗻𝘆, 𝗲𝗮𝗿𝗹𝘆 𝗹𝘂𝗻𝗴 𝗰𝗵𝗮𝗻𝗴𝗲𝘀—𝗯𝗲𝗳𝗼𝗿𝗲 𝘀𝘆𝗺𝗽𝘁𝗼𝗺𝘀 𝘀𝗵𝗼𝘄?

A 2025 research study in a large community cohort looked at antiphospholipid antibodies (aPL) and subclinical interstitial lung disease markers on CT scans.

What they found (in plain English):
- Some aPL were linked to small, early CT changes
- They did not find a clear link to more defined CT “interstitial lung abnormalities” overall
- This is research, not a diagnosis tool, and it doesn’t change care on its own.

💬 Question for you: Have you ever had a CT scan of your chest/lungs?

🔁 If research updates like this help, share this post so more people can find APS information. You can find the full paper in the comments below.

30/12/2025

Read more: https://pubmed.ncbi.nlm.nih.gov/41362190/ on this topic

🧾 New case report (Dec 2025): a patient with bilateral hip osteonecrosis alongside antiphospholipid syndrome (aPL+) and acquired subclinical haemophilia A (factor VIII inhibitor).

Why it’s notable: this kind of overlap is extremely rare and can make clotting lab results harder to interpret — the authors highlight the importance of careful coagulation testing to help avoid delays or misdiagnosis.

Hopeful takeaway: awareness of rarer APS “overlaps” can support faster recognition and safer, timely care. 💙

Find the abstract in the comments below. 👇